Coronavirus, or COVID-19, is an infectious virus that is spreading rapidly around the world and the World Health Organisation (WHO) declared the outbreak a global health emergency within weeks of its identification. As of 11 March, WHO announced that the Coronavirus outbreak has become a global pandemic.Read More
The BiosearchTech Blog
The development of new genomic sequencing techniques and bioinformatics analysis in the last decade has led to massive advances in the diagnosis, prognosis and treatment of disease (1,2).Read More
We’ve recently captured our talented manufacturing teams hard at work building oligos. Please enjoy this short visual insight into LGC Biosearch Technologies.
The largest recorded Ebola Virus Disease outbreak in history continues to devastate the West African region. This epidemic has presented a public health emergency to national and international disease control centers with aid workers tirelessly working to assist affected communities. Ebola is a single-stranded RNA virus that has five known strains, four of which are pathogenic to humans. The current outbreak is a result of the spread of the Zaire ebolavirus (EBOV) strain which previously averaged a 78% mortality rate 1. In a recent update from the World Health Organization, upwards of 2,600 deaths have been reported as result of the viral infection over the last several months 2.
Biosearch Technologies, Inc. (Biosearch), a leader in the development and manufacture of GMP grade oligonucleotides, announced today the relocation of its GMP manufacturing process into a new, state-of-the-art GMP production facility in Novato, California. The 30,000 square foot facility was developed to further expand processes and controls relevant to medical device and molecular diagnostic customers.
Non-squamous, Non-small cell lung cancer (NSCLC), the most common cause of death in the US and globally, has recently been dealt a significant blow as a result of collaborations among teams from UCSF Thoracic Oncology, Kaiser Permanente Research, and the China Clinical Trials Consortium (CCTC) uniting hospitals and universities across mainland China.
Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, and IMDx (privately held), a developer and manufacturer of innovative, clinically impactful molecular test solutions, today announced that Biosearch has licensed access to the BHQ®, CAL Fluor® and Quasar® patents to IMDx. In addition, Biosearch will manufacture cGMP oligonucleotides for IMDx for use in human in-vitro diagnostics.
Biosearch Technologies is proud to sponsor the first IVD Technology Virtual Conference and Tradeshow. This free online conference, held on Tuesday, September 28th, includes a keynote address by Alberto Gutierrez, PhD, Director of the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), and panel discussion on several aspects of the IVD industry.
Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has been awarded a Phase II Small Business Innovative Research (SBIR) grant from the Department of Defense (DoD).
It can be difficult to transition a product from research to commercialization. It’s simply not feasible to conduct pilot testing in a fully GMP compliant setting because of the significant costs associated with meeting the FDA’s stringent regulations. To ensure consistency throughout the product lifecycle, IVD developers need to plan from the very beginning to choose component manufacturers who can match both the economic realities and changing regulatory requirements as a product matures.
Topics: Molecular Diagnostics